Patents by Inventor Don Zhang

Don Zhang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190233399
    Abstract: Crystalline forms of N-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide (1) and its pharmaceutically acceptable salts and compositions thereof useful for the treatment or prevention of diseases or medical conditions mediated through mutated forms of epidermal growth factor receptor (EGFR), such as various cancers, are disclosed.
    Type: Application
    Filed: June 16, 2017
    Publication date: August 1, 2019
    Applicant: Beta Pharma, Inc.
    Inventors: Michael N. Greco, Michael J. Costanzo, Michael A. Green, Jirong Peng, Victoria Lynn Wilde, Don Zhang
  • Patent number: 10239864
    Abstract: Indazole compounds of formula (I) as cyclin-dependent kinase (CDK) and cell-proliferation inhibitors, and therapeutic uses and methods of preparation thereof, are disclosed. These compounds, and pharmaceutically acceptable salts, solvates, prodrugs, and pharmaceutical compositions thereof, are useful for treating diseases and disorders associated with activity of cyclin-dependent kinases, in particular CDK4/6, including but not limited to various cancers and inflammation-related diseases or conditions.
    Type: Grant
    Filed: January 29, 2018
    Date of Patent: March 26, 2019
    Assignee: Beta Pharma, Inc.
    Inventors: Michael Nicholas Greco, Michael John Costanzo, Jirong Peng, Victoria Lynn Wilde, Don Zhang
  • Publication number: 20180148431
    Abstract: Indazole compounds of formula (I) as cyclin-dependent kinase (CDK) and cell-proliferation inhibitors, and therapeutic uses and methods of preparation thereof, are disclosed. These compounds, and pharmaceutically acceptable salts, solvates, prodrugs, and pharmaceutical compositions thereof, are useful for treating diseases and disorders associated with activity of cyclin-dependent kinases, in particular CDK4/6, including but not limited to various cancers and inflammation-related diseases or conditions.
    Type: Application
    Filed: January 29, 2018
    Publication date: May 31, 2018
    Applicant: Beta Pharma, Inc.
    Inventors: Michael Nicholas Greco, Michael John Costanzo, Jirong Peng, Victoria Lynn Wilde, Don Zhang
  • Patent number: 9878994
    Abstract: Indazole compounds of formula (I) as cyclin-dependent kinase (CDK) and cell-proliferation inhibitors, and therapeutic uses and methods of preparation thereof, are disclosed. These compounds, and pharmaceutically acceptable salts, solvates, prodrugs, and pharmaceutical compositions thereof, are useful for treating diseases and disorders associated with activity of cyclin-dependent kinases, in particular CDK4/6, including but not limited to various cancers and inflammation-related diseases or conditions.
    Type: Grant
    Filed: July 24, 2015
    Date of Patent: January 30, 2018
    Assignee: Beta Pharma Inc.
    Inventors: Michael Nicholas Greco, Michael John Costanzo, Jirong Peng, Victoria Lynn Wilde, Don Zhang
  • Publication number: 20170362203
    Abstract: This application discloses novel substituted 2-anilinopyrimidine derivatives, and pharmaceutically acceptable salts, solvates, prodrugs, and compositions thereof, which are useful for the treatment or prevention of diseases or medical conditions mediated by epidermal growth factor receptors (EGFRs), including but not limited to a variety of cancers.
    Type: Application
    Filed: December 11, 2015
    Publication date: December 21, 2017
    Applicants: Beta Pharma, Inc., Beta Pharma (Shanghai) Co., Ltd.
    Inventors: Jirong Peng, Michael John Costanzo, Michael Nicholas Greco, Michael Alan Green, Victoria Lynn Wilde, Don Zhang
  • Patent number: 9820721
    Abstract: This application discloses aspiration/biopsy needle apparatus, devices containing these needle apparatus, and methods using these needle apparatus and devices for aspiration or biopsy of samples, in particular biological samples from mammalian subjects. The novel aspiration/biopsy needle systems can find wide applications in the manufacture of fine needle aspiration (FNA)/biopsy devices for convenient cell harvesting and tissue sampling and analysis.
    Type: Grant
    Filed: April 23, 2015
    Date of Patent: November 21, 2017
    Assignee: Beta Pharma, Inc.
    Inventors: Jirong Peng, Don Zhang
  • Publication number: 20170210726
    Abstract: Indazole compounds of formula (I) as cyclin-dependent kinase (CDK) and cellproliferation inhibitors, and therapeutic uses and methods of preparation thereof, are disclosed.
    Type: Application
    Filed: July 24, 2015
    Publication date: July 27, 2017
    Applicant: Beta Pharma, Inc.
    Inventors: Michael Nicholas Greco, Michael John Costanzo, Jirong Peng, Victoria Lynn Wilde, Don Zhang
  • Patent number: 9359370
    Abstract: The invention relates to 4-[(3-ethynylphenyl)amino]-6,7-benzo-12-crown-quinazoline hydrochloride, its new crystalline forms, its therapeutic usage for treatment of diseases mediated by EGFR kinase and its combinatory therapeutic usage together with other therapeutic agents. The invention also provides synthetic methods for preparation of 4-[(3-ethynylphenyl)amino]-6,7-benzo-12-crown-quinazoline hydrochloride, its new crystalline forms, and the relevant synthetic intermediates for synthesis of 4-[(3-ethynylphenyl)amino]-6,7-benzo-12-crown-quinazoline hydrochloride.
    Type: Grant
    Filed: July 31, 2014
    Date of Patent: June 7, 2016
    Assignee: Beta Pharma, Inc.
    Inventors: Yinxiang Wang, Guojian Xie, Lieming Ding, Fenlai Tan, Yunyan Hu, Wei He, Bin Han, Wei Long, Yong Liu, Haima Ai, Charles Davis, Don Zhang
  • Publication number: 20150305724
    Abstract: This application discloses aspiration/biopsy needle apparatus, devices containing these needle apparatus, and methods using these needle apparatus and devices for aspiration or biopsy of samples, in particular biological samples from mammalian subjects. The novel aspiration/biopsy needle systems can find wide applications in the manufacture of fine needle aspiration (FNA)/biopsy devices for convenient cell harvesting and tissue sampling and analysis.
    Type: Application
    Filed: April 23, 2015
    Publication date: October 29, 2015
    Applicant: BETA PHARMA, INC.
    Inventors: Jirong Peng, Don Zhang
  • Patent number: 9163010
    Abstract: The present invention relates to new indolinone compounds and their pharmaceutically acceptable salts and prodrugs for treating and preventing VEGFR related cellular disorders such as cancer.
    Type: Grant
    Filed: April 6, 2012
    Date of Patent: October 20, 2015
    Assignee: Beta Pharma, Inc.
    Inventors: Don Zhang, Guojian Xie
  • Publication number: 20140343082
    Abstract: The invention relates to 4-[(3-ethynylphenyl)amino]-6,7-benzo-12-crown-quinazoline hydrochloride, its new crystalline forms, its therapeutic usage for treatment of diseases mediated by EGFR kinase and its combinatory therapeutic usage together with other therapeutic agents. The invention also provides synthetic methods for preparation of 4-[(3-ethynylphenyl)amino]-6,7-benzo-12-crown-quinazoline hydrochloride, its new crystalline forms, and the relevant synthetic intermediates for synthesis of 4-[(3-ethynylphenyl)amino]-6,7-benzo-12-crown-quinazoline hydrochloride.
    Type: Application
    Filed: July 31, 2014
    Publication date: November 20, 2014
    Inventors: Yinxiang Wang, Guojian Xie, Lieming Ding, Fenlai Tan, Yunyan Hu, Wei He, Bin Han, Wei Long, Yong Liu, Haima Ai, Charles Davis, Don Zhang
  • Patent number: 8822482
    Abstract: The invention relates to 4-[(3-ethynylphenyl)amino]-6,7-benzo-12-crown-quinazoline hydrochloride, its new crystalline forms, its therapeutic usage for treatment of diseases mediated by EGFR kinase and its combinatory therapeutic usage together with other therapeutic agents. The invention also provides synthetic methods for preparation of 4-[(3-ethynylphenyl)amino]-6,7-benzo-12-crown-quinazoline hydrochloride, its new crystalline forms, and the relevant synthetic intermediates for synthesis of 4-[(3-ethynylphenyl)amino]-6,7-benzo-12-crown-quinazoline hydrochloride.
    Type: Grant
    Filed: July 7, 2009
    Date of Patent: September 2, 2014
    Assignee: Beta Pharma, Inc.
    Inventors: Yinxiang Wang, Guojian Xie, Lieming Ding, Fenlai Tan, Yunyan Hu, Wei He, Bin Han, Wei Long, Yong Liu, Haima Ai, Charles Davis, Don Zhang
  • Publication number: 20120258995
    Abstract: The present invention relates to new indolinone compounds and their pharmaceutically acceptable salts and prodrugs for treating and preventing VEGFR related cellular disorders such as cancer.
    Type: Application
    Filed: April 6, 2012
    Publication date: October 11, 2012
    Applicant: Beta Pharma, Inc
    Inventors: Don Zhang, Guojian Xie
  • Publication number: 20110182882
    Abstract: The invention relates to 4-[(3-ethynylphenyl)amino]-6,7-benzo-12-crown-quinazoline hydrochloride, its new crystalline forms, its therapeutic usage for treatment of diseases mediated by EGFR kinase and its combinatory therapeutic usage together with other therapeutic agents. The invention also provides synthetic methods for preparation of 4-[(3-ethynylphenyl)amino]-6,7-benzo-12-crown-quinazoline hydrochloride, its new crystalline forms, and the relevant synthetic intermediates for synthesis of 4-[(3-ethynylphenyl)amino]-6,7-benzo-12-crown-quinazoline hydrochloride.
    Type: Application
    Filed: July 7, 2009
    Publication date: July 28, 2011
    Applicant: Beta Pharma, Inc.
    Inventors: Yinxiang Wang, Guojian Xie, Lieming Ding, Fenlai Tan, Yunyan Hu, Wei He, Bin Han, Wei Long, Yong Liu, Haima Ai, Charles Davis, Don Zhang
  • Patent number: 7078409
    Abstract: The present invention is directed to a compound having the structure wherein A is a 7–18 membered ring that comprises 0 to 6 heteroatoms selected from O, S, and N; R1 is selected from the group consisting of hydrogen, halogen, substituted or unsubstituted C1-8alkyl, substituted or unsubstituted C2-8alkenyl, substituted or unsubstituted C2-8alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, and substituted or unsubstituted heterocyclyl; m is an integer from 0 to 3; X is selected from the group consisting of NR2, CHR3, O, or S; wherein R2 and R3 are each individually H or C1-8alkyl; R is selected from the group consisting of unsubstituted aryl, and substituted or unsubstituted heteroaryl, substituted or unsubstituted aryl-(C1-3)alkyl, substituted or unsubstituted aryl-(C3-7)cycloalkyl, substituted or unsubstituted heteroaryl-(C1-3)alkyl, and substituted or unsubstituted heteroaryl-(C3-7)cycloalkyl; and pharmaceutically acceptable salts thereof; with the proviso that if A is
    Type: Grant
    Filed: March 26, 2003
    Date of Patent: July 18, 2006
    Assignee: Beta Pharma, Inc.
    Inventors: Don Zhang, Guojian Xie, Charles Davis, Zhengzhuang Cheng, Hang Chen, Yinxiang Wang, Mehrnaz Kamal
  • Publication number: 20050148554
    Abstract: The invention encompasses novel compounds of Formula I, which are anti-inflammatory and anti-thrombotic agents. The invention also encompasses certain pharmaceutical compositions and methods for treatment of cyclooxygenases (COX-1 and COX-2) mediated diseases comprising the use of compounds of Formula I. The above compounds may be used as a combination therapy with low-dose aspirin, NSAIDs, or selective COX-2 inhibitors to treat chronic cyclooxygenases mediated diseases or conditions while simultaneously reducing the risk of thrombotic cardiovascular events.
    Type: Application
    Filed: November 12, 2004
    Publication date: July 7, 2005
    Inventors: Don Zhang, Guojian Xie, Zhengwei Huan, Hang Chen, Charles Davis
  • Publication number: 20040048883
    Abstract: The present invention is directed to a compound having the structure 1
    Type: Application
    Filed: March 26, 2003
    Publication date: March 11, 2004
    Inventors: Don Zhang, Guojian Xie, Charles Davis, Zhenzhuang Cheng, Hang Chen, Yinxiang Wang, Mehrnaz Kamal